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Abstract 
High grade brain tumours are treated with surgery, 
chemotherapy and radiation therapy and despite such 
aggressive treatment, can recur in a short span of time. 
MRI scan has been the conventional diagnostic modality 
to diagnose recurrence, although at times it becomes 
difficult for the neuroradiologists to differentiate 
between tumour recurrence and radiation necrosis. 
Herein lies the emergent need to explore the efficacy of 
functional imaging to assist in this diagnostic 
challenge.Recent studies have sought to do so with 
promising implications, which we have attempted to 
summarize in this review. 
Keywords: Functional imaging, neuro-oncology; tumor 
recurrence; treatment necrosis; perfusion. 
Introduction 
Despite aggressive treatmenrt regimes for high grade 
brain tumours, recurrence remains inevitable.1 For a 
considerable amount of time, conventional contrast 
enhanced MR imaging has been the mainstay of 
assessing post treatment tumour recurrence, especially 
in CNS neoplasms.The usual indicators of a recurrent 
tumour on follow up MRI include progressive 
enlargement of lesion, causing mass effect and 
infiltration of corpus callosum; whereas the 
enhancement pattern following a Swiss cheese or 
spreading wavefront pattern is more indicative of 
radiation necrosis.2 Over the years considerable overlap 
between these two types has been observed which has 
prompted new research efforts into investigating 
advanced non-invasive imaging methods measuring 
physiological tumour properties.3 Novel modern day 
research centers on bringing forth the capabilities of MR 
perfusion in exploiting the functional differences at the 
cellular level between recurrent or progressive tumour 
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Figure : Enhancing right frontal lobe lesion with perfusion showing raised CBV along medial margins and center representing viable tumour, supporting a diagnosis of recurrence.
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growth from treatment-induced necrosis after radiation 
therapy.These include increased cell proliferation with 
neo-angiogenesis in case of tumour; and liquefactive 
necrosis, vascular hyalinization and endothelial damage 
in case of radiation induced changes.4 The observed 
clinical symptoms vary from none to significant 
neurological deficit predominantly affecting the white 
matter. Vermaet al.,5 reported an incidence of 3–24% for 
radiation necrosis, showing a direct correlation with the 
dose of radiation, duration and volume of targeted brain 
parenchyma. 
Technique 
In perfusion scanning, successive images are obtained 
during the first pass of contrast. There are two methods 
of obtaining perfusion sequences namely dynamic 
susceptibility-weighted contrast-enhanced (DSC) and 
dynamic contrast-enhanced (DCE) imaging. In DSC-MRI, 
the susceptibility effect of contrast causes a T2 signal 
drop in DSC-MR thus allowing measurement of 
haemodynamic parameters: relative cerebral blood 
volume (rCBV), relative peak height (rPH), and 
percentage of signal-intensity recovery (PSR). Higher 
rCBV indicates highly permeable blood vessels as in the 
case of tumour neo-angiogenesis whereas lower values 
stipulate treatment necrosis reducing blood flow.5 CBV 
data is compared with the contralateral side for 
normalization hence the term relative.6 In DCE-MRI, 
rapid sequence T2 imaging is used to measure signal 
intensities of contrast bolus which reflects lesion 
perfusion, permeability and extracellular volume. 
However very few precedents are found in literature that 
show compelling results in application of DCE-MRI to 
the question of tumour recurrence versus radiation 
necrosis.5 
Review of Evidence 
Prager et al.7, conducted perfusion analysis in post 
treatment enhancing lesions for patients with primary 
high grade gliomas. They reported lower rCBV values in 
treatment related changes, rCBV lesion (P = 0.003) and 
rCBVROI (region of interest) (P = 0.011). An optimized 
rCBV lesion threshold of ≥1.27 had 86.5% sensitivity and 
83.3% specificity with AUC (area under curve) of 0.863 
for the diagnosis of recurrence.Barajas et al.8, performed 
a retrospective review of 27 patients that underwent 
gamma knife radiosurgery for metastatic lesions of the 
brain.Upon follow up patients that presented with 
enhancing lesions on conventional imaging were 
selected and ROI were drawn around the entire contrast-
enhancing region.Their observations stipulated lower 
rCBV (P <0.01) in lesions with necrosis. A cutoff rCBV 
value of 1.52 in enhancing lesions withstood cross-
validation with a sensitivity of 91.30% and specificity of 
72.73 for tumour recurrence. 
Sugahara et al.9, were amongst the initial investigators 
to pave the way for future research efforts that may 
solidify the role of MR perfusion in this area. In their 
landmark paper they reported higher normalized ratios 
of rCBV in the tumour recurrence group compared to 
those of the non-neoplastic group. The differences 
between the two groups reached statistical significance, 
P value 5.03 and 0.02, respectively. A sensitivity of 50% 
and a specificity of 90% for perfusion-sensitive contrast-
enhanced MR imaging at a cutoff value of 1.0 for 
normalized rCBV ratios was reported.They also 
presented a detailed overview of overlap in normalized 
rCBV ratios between the two groups. According to them, 
the factors that may have affected the ratios include 
coexisting neoplastic and necrotic tissue, the affected 
vessels in irradiated tissue being prone to vascular 
phenomena such as formation of aneurysmal or 
telangiectatic collaterals resulting in larger rCBV ratios, 
and finally post radiation petechial haemorrhages that 
reduce the rCBV when occurring in areas of tumour 
recurrence.Young et al.10,also reported that patients in 
their study group comprising of treated glioblastoma 
with progressive disease demonstrated significantly 
higher median rCBV with P=0.009. 
In a recently published meta-analysis, Chuang MT et 
al.11, reviewed 13 articles that encompassed a total of 
397 patients not restricted by tumour type as these 
included primary plus metastatic lesions providing a 
bigger picture to comprehend the versatile role of MR 
perfusion in lesion characterization.They concluded that  
average rCBV was significantly higher in tumour 
recurrence compared with radiation injury (all P < 
0.05).Bobek-Billewicz et al.12, compared the efficacy of 
MR perfusion over MR spectroscopy in differentiating 
true recurrence from radiation injury. They made 
observations that show statistically significant 
difference in terms of rCBV between tumour recurrence 
and radiation injury group (rCBVmax p < 0.001, 
rCBVmean p < 0.005) with mean rCBV being more 
plausible as a differing factor than max rCBV. 
Conclusion: 
In the light of available evidence as briefed in our review, 
it would be safe to conclude that functional MR imaging 
has far progressed over the years as a potential non-
invasive tool for differentiating between tumour 
recurrence and radionecrosis.MR perfusion has been 
consistently reported as a promising adjunct for the 
distinction between recurrent tumour and radiation 
injury.  
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